ADORA2A and cancer: Some pre-clinical studies including anti-CD73 antibody, BMS-986179 [207], CPI-006 [208], A2AR antagonist NIR178 (PBF-509) [209], inupadenant (EOS-850) [210], Ciforadenant (CPI-444) [211,212], and A2AR/A2BR dual antagonist AB928 [213,214] showed significant tolerability in humans for cancer treatment [188].